Nektar Therapeutics Q2 EPS $(0.27) Beats $(0.28) Estimate, Sales $20.50M Miss $21.79M Estimate
Portfolio Pulse from Benzinga Newsdesk
Nektar Therapeutics reported Q2 losses of $(0.27) per share, beating the analyst consensus estimate of $(0.28) by 3.57%. However, the company's quarterly sales of $20.50 million missed the analyst consensus estimate of $21.79 million by 5.92%.
August 08, 2023 | 8:54 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Nektar Therapeutics reported better than expected Q2 EPS but missed on sales. This mixed result could lead to volatility in the stock price.
Nektar Therapeutics reported a better than expected EPS for Q2, which is a positive signal for investors. However, the company missed on sales, which is a negative signal. These mixed results could lead to uncertainty and volatility in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100